Daniel Latham

Daniel Latham is an experienced executive in the pharmaceutical and medical device industry, currently serving as Executive Director - Global Program Leader at Orchard Therapeutics since November 2022, focusing on the development and commercialization of ex-vivo gene therapeutics for neurometabolic rare diseases. Prior to this role, Daniel held several leadership positions at Novartis from 2007 to 2022, including Head of Connected Health Product Development and Head of Device Development, where responsibilities encompassed managing global teams, developing digital health solutions, and overseeing the technical strategy for drug-device combinations. Earlier career experiences include project management roles at SSL International plc and regulatory affairs at Granton Medical Limited. Daniel holds a PhD in Controlled Drug Delivery Systems from Queen Mary University of London, as well as a Master’s and Bachelor's degree from The University of Sheffield in Medical Physics and Clinical Engineering and Biomaterials, respectively.